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ABSTRACT 
Objectives: To produce a summary of the published evidence of the barriers and facilitators for 
hospital-based routine HIV testing in high-income countries.  
Methods: Electronic databases were searched for studies, which described the offer of HIV 
testing to adults attending emergency departments (EDs) and acute medical units (AMUs) in the UK 
and US, published between 2006-15. Other high-income countries were not included, as their 
guidelines do not recommend routine testing for HIV. The main outcomes of interest were HIV 
testing uptake, HIV testing coverage, factors facilitating HIV screening and barriers to HIV testing. 
Fourteen studies met the pre-defined inclusion criteria and critically appraised using mixed methods 
appraisal tool (MMAT). 
 Results: HIV testing coverage ranged from 9.7%-38.3% and 18.7%-26% while uptake levels were 
high (70.1-84% and 53%-75.4%) in the UK and US, respectively. Operational barriers such as lack of 
time, the need for training and concerns about giving results and follow up of HIV-positive results, 
were reported. Patient-specific factors including female sex, old age and low risk perception 
correlated with refusal of HIV testing. Factors that facilitated the offer of HIV testing were venous 
sampling (vs. point-of-care tests), commitment of medical staff to HIV testing policy and support 
from local HIV specialist providers.   
Conclusions: There are several barriers to routine HIV testing in EDs and AMUs. Many of these 
stem from staff fears about offering HIV testing due to the perceived lack of knowledge about HIV. 
Our systematic review highlights areas which can be targeted to increase coverage of routine HIV 
testing. 
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INTRODUCTION: 
 HIV infection is a major global public health threat and is responsible for significant morbidity and 
mortality (1), despite recent progress in treatment and care. (2) Public Health England reports that 
13% (13,500) of the 101,200 people who were estimated, to be living with HIV in the UK in 
2015were unaware of their HIV infection. (3) Similarly, the Centres for Disease Control and 
Prevention (CDC) surveillance data shows that 13% of the 1.2 million people living with HIV in the 
United States (US) in 2013 were undiagnosed. (4) Furthermore, 39 % of those diagnosed with HIV in 
the United Kingdom (UK) in 2015 were diagnosed with CD4 counts < 350 cells/mm3, (3) and 46 % of 
people diagnosed with HIV infection in the US in 2015 were diagnosed with CD4 counts < 200 
cells/mm3 (4) Late-stage HIV diagnosis is associated with increased morbidity and mortality, (5) 
greater onward transmission (6,7) and high cost of treatment and care. (8) 
Historically HIV testing was targeted - based on clinical suspicion and risk assessment. There is now 
evidence to suggest that targeted strategies result in missed HIV cases, sometimes even when 
patients present with HIV-associated conditions. (9-14) A recent randomised trial comparing 
universal testing with targeted testing in an emergency department (ED) in the US, showed that 
routine testing, defined as testing regardless of risk or clinical condition, identified more HIV cases 
than targeted testing. (15) 
In recognition of the benefits of early HIV diagnosis the CDC published its revised HIV testing 
guidelines in September 2006 recommending routine opt-out HIV screening for all people aged 13-
64 attending any healthcare setting, including the ED, in areas where the prevalence of diagnosed 
HIV infection in the population exceeds 0.1%. (16) The UK national HIV testing guidelines, (released 
in 2008) recommended HIV screening in various healthcare settings including all medical admissions 
in patients aged 16-59 in areas of HIV prevalence of more than 2 in 1000 population. (17-19) Despite 
the recommendations for routine offer of HIV testing a systematic review showed that the HIV 
testing coverage in settings where routine testing is recommended was just 29.5%. (20) 
We aim to systematically review the literature to identify the facilitators and barriers to HIV 
screening in emergency departments (EDs) in the US and in acute medical units (AMUs) and EDs in 
the UK; other high-income countries were not included, as their guidelines do not recommend 
routine testing for HIV (21-23) Acute medical units serve as extensions of EDs in many hospitals in 
the UK, where patients are transferred directly from EDs, pending full admission to wards or 
discharge. We focused on EDs and AMUs as they are attended by a large number of patients a 
proportion of whom may not have access to other healthcare facilities, especially in the US. They are 
also the point of entry into health services for many. We hope to produce a summary of existing 
evidence that will help stakeholders and policy makers implement routine HIV testing and translate 
into practice what is already recommended.  
METHODS 
This review was conducted and presented in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) recommendation (24) (Supplementary Material 1). 
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We searched for publications which report on at least one of the following primary outcomes:  
1.Coverage of HIV testing (proportion of people tested for HIV out of those eligible for testing, as per 
the guidelines) and/or HIV testing uptake (proportion of patients accepted the HIV test offer out of 
those offered a routine HIV test) in EDs/AMUs or  
2. Facilitators (factors helping in increasing the offer of HIV testing and/or uptake) and /or Barriers 
(factors hindering the offer of HIV testing and/or uptake) of HIV testing in EDs/AMUs.  
Electronic databases (MEDLINE and EMBASE) were searched for studies reporting on routine HIV 
screening (defined as the offer of HIV testing regardless of clinical presentation or HIV risk) as per 
CDC or UK HIV testing guidelines. We searched for terms, which referred to “facilitators”, “barriers”, 
“coverage”, “uptake”, “routine HIV testing”, “UK” and “US” (Supplementary Material 2) 
Only studies including adults aged ≥ 13 years old (US) and ≥ 16 years old (UK) as per UK and CDC 
guidelines, attending EDs in the US or AMUs/EDs in the UK were included. Studies exploring the 
attitudes of providers of routine HIV screening for the above populations were also included.  
No restriction on study design was applied. Only articles published in English language and in peer-
reviewed journals in the period from 2006 and 2008 for American and British studies (reflecting the 
years when relevant recommendations were introduced in each country) respectively, up to 2015 
were included. Grey literature and studies reporting on targeted, HIV tests based on clinical 
suspicion and/or risk assessment, HIV testing were excluded. We also manually searched the 
bibliographies of relevant articles. If more than one article reported on the same study population, 
only the article that provided most completed data was included. Review articles were also excluded 
to avoid over-lap. 
The primary investigator (AE) conducted all searches, and reviewed all relevant abstracts and full-
length articles and extracted data using a standardised form (Supplementary Material 3). A second 
independent investigator (KS) verified all the steps. Disagreements were resolved by consensus.      
The mixed methods appraisal tool (MMAT) (25) was used to look for sources of bias in the studies.  
We did not perform a meta-analysis, as included studies were heterogeneous,.  Hence, narrative 
synthesis and summary of the evidence was carried out. We carried out a thematic analysis for 
facilitators and barriers to HIV testing. After thorough review of the selected studies, we deducted 
the themes and categorised the findings according to whether they represented factors that helped 
or hindered HIV testing.      
RESULTS  
Study selection 
The process of study selection for inclusion is described in Figure 1. Fourteen papers, 7 British and 7 
American, were included in the review (Table 1).   
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Study characteristics: 
Seven UK-based studies were included. (26-32) Six of them were quantitative studies (26, 28-32) and 
one was a qualitative study. (27) Three studies were pilots of 3-month duration (26, 31, 32) whilst 
the other three studies reported on experience of implementing policies of routine HIV testing for 
the duration of 12 months, (29) 21 months, (30) and 30 months. (28) The qualitative study (27) 
examined staff views about HIV testing before and after the implementation of the HIV testing 
programme. (27) (26, 27) 
Seven American studies were also included in the review (33-39). Most of them were quantitative 
(33-38) and one was a mixed-methods study. (39) Three studies described implementation of 
policies, for HIV screening in EDs of 9-months, (35) 56-months (36) and 60-months (39) durations, 
and reported on HIV testing coverage, uptake, barriers and facilitators. Further 3 studies explored 
staff and patients’ views about HIV screening (33, 37, 38) and the seventh was a pilot study reporting 
on HIV testing uptake and coverage. (34) 
Risk of bias within studies 
A summary of risk of bias assessment in each quantitative study (12 in total; 6 British and 6 
American) included in the review using MMAT is shown in Supplementary Material 4. All but 2 (26, 
38) of the 12 reports did not compare patient characteristics between all patients eligible for HIV 
screening and those approached for testing. In the absence of such data, selection bias and targeting 
of high-risk groups of patients could not be ruled out. Patients approached for testing may be 
different from the overall population eligible for routine screening. Studies, which used surveys, 
focus group and in-depth interviews, selected participants via a convenience sample or non-
systematic approach for selection. (26, 37, 38) This may have resulted in selection bias and 
participants may not be representative of all patients attending EDs.  
The qualitative study (27) scored 100% on the MMAT score whereas the mixed-methods study (39) 
scored 75%. In the latter study, there was no data about the representativeness of the sample in 
relation to the population, in the quantitative component. The qualitative component did not give 
consideration to the influence the researchers may have had on study findings.  
Results of individual studies 
HIV testing uptake, coverage and linkage to care 
As shown in table 1, the HIV testing uptake ranged from 53% to 84%. In the UK, HIV test uptake in 
EDs (62 63%), (26, 28) was lower than AMUs (70-84%), (26, 30, 32). In the US, the uptake levels in 
EDs ranged from 53% to 75%. (37, 36) Despite high levels of uptake, the HIV testing coverage in the 
UK and US was (10% to 38%)(26, 29-32) and 19% to 26% (34, 35), respectively. Among those 
diagnosed, 88% to 100% in the UK and 74% to 100% in the US were linked into care. 
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Barriers to HIV testing 
Stigma, and confidentiality and privacy concerns 
In a study by Thorton et al (27), staff identified HIV as an “exceptional” condition and suggested that 
this was a barrier to the offer and uptake of HIV testing in settings other than sexual health and 
antenatal clinics. However, they also felt that HIV testing in medical settings would help in 
normalising and reducing the stigma attached to HIV. (27) Staff also raised confidentiality and 
privacy concerns as an obstacle to offering HIV testing in their settings, particularly in EDs. (27) Lack 
of privacy was also reported as a hurdle to HIV test offer by 58% of ED staff and 44% of AMU staff 
(26). In another study, 35% of patients and 38% of staff expressed similar concerns regarding 
confidentiality and privacy of HIV testing in a setting like ED. (38) 
Staff fears about offering HIV tests 
Staff expressed concern that they did not have the specialist knowledge needed to offer an HIV test.  
(27) 
During semi-structured interviews with 8 staff members working in an ED, Knapp et al reported that 
participants identified lack of training as a factor that hindered offer of HIV testing. (39) 
Similarly another study found that 82% and 65% of staff members in ED and AMU, respectively, 
reported that they would require additional training prior to offering an HIV test. (26) 
Operational barriers 
Several operational barriers such as lack of time, concerns over results’ handling and provision of 
follow up were identified as obstacles to HIV testing offer in both the UK and US. (26, 27, 32, 33, 38) 
In the UK, more than 50% of staff in an ED and 40% of an AMU staff identified insufficient time as a 
hurdle to the offer of HIV testing. (26) Staff from both settings also reiterated this concern during 
focus groups. (27) 
In the same focus groups in the UK, staff raised concerns about giving an HIV-positive result and 
referring HIV-positive patients for care. (27) 
In an American study, clinical staff in ED were asked about the perceived barriers to HIV testing in ED 
before and after implementing a 6-month routine HIV testing project in ED (33) At the study, more 
staff members identified time constraints (62% versus 51% at baseline) and concerns regarding 
follow-up (59% versus 50% at baseline) as obstacles for HIV test offer in ED. Conversely, concerns 
about other resources being inadequate, decreased from 70% to 60% over the study period. (33) 
Another American study showed that 60% and 35% of staff identified lack of time and concerns 
about provision of follow up, respectively as two factors that impeded offer of HIV testing in ED. (34) 
Semi-structured interviews with staff identified other barriers to the sustainability of the offer of HIV 
testing such as lack of senior leadership engagement; insufficient involvement of frontline staff in 
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the planning process; and inadequate systems of monitoring of and feedback about the offer and 
uptake of HIV testing to staff in the frontline. (39) 
The short average length of stay in AMUs was been identified as a hindering factor to HIV testing in 3 
UK-based studies. (26, 29, 30) 
Facilitators of HIV testing 
Partnership between ED/AMU medical staff and local specialist units 
Eight studies reported partnership between the ED/AMU staff and local HIV (26-28, 30, 31) or 
infectious diseases units (32, 35, 39). The ED/AMU staff offered the HIV tests and the specialist HIV 
teams prepared patient information sheets, trained medical teams on how to offer an HIV test and 
handled results and referral for care. Three of these studies described prelaunch meetings attended 
by all relevant stakeholders to define testing pathways and model of delivery as beneficial. (30-32)  
Operational facilitators 
Operational factors that were recognised as facilitators for the offer of HIV testing included non-
written consent, non-targeted testing, simple results’ system and not using point of care tests 
(POCT). In all UK testing projects verbal consent documented in medical notes was sufficient. (26-32) 
In 4 studies, venous sampling was used (rather than POCT which would require immediate provision 
of results and post-test counselling etc.) (29-32). In three studies, results were handled via a ‘no 
news is good news’ policy and only patients with a positive test result or those requiring repeat 
testing for any reason were contacted. (30-32) Staff in AMU recognised that importance of routine 
offer of testing to all patients in facilitating HIV testing (as opposed to targeted testing). (27)   
  
In the US, Lin X et al (35) reported that operational changes to their HIV testing pathway impacted 
on the offer of HIV testing. Initially, selected staff dedicated only to HIV testing carried out opt-in HIV 
testing with POCT in their ED. Training all existing ED staff to offer HIV testing, using the electronic 
health record to prompt HIV testing for eligible patients, and switching from POCT to venous 
sampling for laboratory testing resulted in increased testing levels from 17% to 26%. (35) Another 
study also identified lack of written consent and removing lengthy pre-test counselling requirements 
as a factor which favoured the offer of HIV testing. (34)  
Commitment and enthusiasm of medical staff offering the HIV test 
The high-level commitment and motivation of medical staff (especially nurses) offering HIV tests was 
identified in two UK-based studies as a facilitator of offering HIV testing. (30, 31) Moreover, 
Rayment et al showed that involvement of nurses in HIV testing together with adding blood 
sampling based HIV testing to oral fluid testing, resulted in an increase in HIV testing level from 11% 
to 29%. (28) An American study evaluating a 5-year sustainability of HIV rapid testing in ED identified 
that success was dependant on the enthusiasm of 2 clinical champions in ED. (39)      
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Patient-specific factors  
As described above uptake of HIV testing when offered was high in most of the studies reviewed. 
Four studies (26, 32, 34, 36) showed that uptake of HIV testing was higher in younger age groups. 
Male sex was also associated with increased uptake of testing in two studies which reported this. 
(26, 36) As shown in table 1, perception of low HIV risk among patients was reported in 3 studies as 
a reason for declining an offer of HIV testing. (32, 37, 38) 
DISCUSSION 
Routine HIV testing has already been shown to be feasible, acceptable by both patients and staff, 
effective in identifying new HIV cases and cost-effective. (40-44) Despite this, studies have shown 
that routine HIV testing in non-specialist settings remains low (20, 45).  
We found that uptake among those offered was high suggesting that the barriers lie more with 
providers rather than patients. Medical staff identified some operational barriers to offering HIV 
testing such as time constraints and the need for more training. They expressed concerns about 
giving positive results and worried about what follow up patients would receive, despite the 
existence of referral pathways. A recent report from the UK showed how these barriers were 
successfully addressed in ED using ‘notional’ consent where staff ordered an HIV test for all patients 
requiring a blood test. Patients could decline testing after they had read a comprehensive leaflet. 
This innovative approach raised testing rates from 2.9% to 61%. (46) In addition, it had identified 
40% of the newly diagnosed patients compared to 25% diagnosed in Sexual Health clinics. (47) 
‘Notional’ consent may not be a fully informed consent, however, diagnosing new infections earlier 
might outweigh any loss in patients’ autonomy. Our review also identified some patient-specific 
factors that correlated with refusal of HIV test offer such as female gender, old age and low risk 
perception. The higher rates of HIV test uptake among younger age groups and males might be 
explained, in part, by the high HIV risk-perception due to multiple sexual partners among young 
people and same-sex relationships among men.     
We identified factors which seem to promote the offer of HIV testing. Several studies reported that 
blood sampling was preferred over POCT, which compelled immediate provision of results. The 
rationale seems to be that waiting for the return of the blood sample result would give staff time to 
prepare for the giving of the result.  Staff also emphasised securing organisational buy-in for the 
testing policy. Another important facilitating factor from both countries that helped increase the 
number of HIV tests offered was the involvement of nurses and their ownership of the HIV testing 
initiative.  
The less than optimal coverage of HIV testing in EDs and AMUs is due to low offer of testing rather 
than low uptake. If medical teams were to engage better with the offer of HIV testing, it is likely the 
reservations and anxieties currently experienced will be alleviated. In turn, this might result in even 
higher levels of HIV test uptake by patients. This is supported by the fact that the HIV test uptake 
levels in antenatal clinics in both UK and US have been consistently over 90% in recent years after 
initial low offer and uptake levels in the first few years after policy implementation. (3, 4) 
Furthermore, normalising HIV as a condition and embedding HIV testing within standard clinical care 
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may overcome some of the operational barriers commonly reported by medical facilities providers. 
However, targeted HIV testing may still be needed to complement routine HIV testing strategies 
considering the low coverage of the latter.   
As described above the integration of a non-rapid HIV test, which requires a verbal consent only (as 
for other investigations), within the normal clinical duties for ED/AMU staff may well reduce 
provider related barriers to offering HIV tests. They would simply have to take another sample (for 
HIV) when taking blood for other tests. However, close cooperation with local HIV specialist teams is 
paramount for sustaining such initiatives. Local specialist HIV teams could provide on-going training 
for general medical staff about HIV testing and the rational for testing guidelines, and help handle 
the results and linkage to care. On-going support from and collaboration with specialist teams would 
also help to alleviate fears about HIV result giving and therefor the offer of HIV testing in the first 
place. In the longer term healthcare workers’ fears should not be a barrier to offering more rapid 
HIV testing.  
Limitations  
Our review has some limitations to be considered. Methodological limitations of individual studies 
could result in mis-leading overall conclusions. Some of the included studies lacked data on 
important outcomes such as uptake and coverage of HIV testing and so our summaries on these 
outcomes are based on very few studies. Moreover, some of the UK studies were in two different 
clinical settings i.e. AMUs and EDs. This may affect the validity of the thematic analysis as some of 
the facilitators and/or barriers were only identified in two or three studies. Furthermore, studies 
were a mixture of proof-of-concept studies and effective sustainable implementation initiatives. 
Finally, It is not possible to extrapolate the conclusions of this review to other international 
healthcare settings.     
Recommendations and conclusions  
Providers considering the introduction of routine HIV screening in medical settings, as per CDC and 
UK guidelines, would need to ensure adequate funding, training, retraining as staff changes, clinical 
support and clear referral pathways as well as prior engagement with stakeholders to encourage 
motivation to change practice. Models of delivery and specific roles should be identified in advance. 
For instance, decisions should be made about the target population and setting (ED or AMU), staff 
offering the test (doctors or nurses or both) and type of HIV test (POCT or standard serology). Also, 
the supportive role of local HIV team should be clarified. Based on published papers successful 
approaches included training of ED/AMU staff, creating patient and staff information leaflets, and 
taking a leading role in handling positive results and linkage to care. Furthermore, senior leadership 
of organisations need to show commitment funding and support of the policy for routine HIV 
testing. Creation of a system for monitoring, audit and feedback to frontline staff would also be 
beneficial. Other important stakeholders to involve would be local public health officials. Of concern, 
despite the fact that American and British HIV testing guidelines have recommended routine testing 
since 2006 and 2008 respectively, the adherence to these recommendations has not been high. Our 
systematic review has identified areas which providers may target to improve this which if 
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successfully implemented could help to normalise HIV, dramatically increase knowledge of HIV 
status, promote HIV prevention and ultimately avert unnecessary morbidity. 
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Figure1: The process of study selection for inclusion in the  
review based on PRISMA guidance (46)  
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Table1. Summary of included British and American studies results  
1st author, 
country 
(year)  
Citation 
Type of 
study 
Setting and 
population 
Duration 
of study 
(months) 
Type of 
HIV test & 
staff 
offering 
test 
HIV 
test 
offer ¶ 
HIV test 
uptake § 
HIV 
testing 
coverage Ι 
Number of 
new HIV 
diagnoses 
Proportion 
of new 
cases 
linked to 
care ¶¶  
Barriers to HIV testing 
§§ 
Facilitators of HIV 
testing Θ 
Rayment  
UK (2013) 
(28) 
Quantitative 
(policy 
report) 
Patients 
aged 16-65 
attending 
ED 
30 Non-rapid 
oral fluid 
(Serology 
added 
later);  
Existing 
ED staff 
15.4%  
6868/ 
44582 
63%  
4327/ 
6868 
9.7%  
4327/ 
44582 
13 100% 1- Competing priorities, 
as the result of 
increasing working 
pressure.  
 
1-Introduction of 
serology testing in 
addition to the oral 
fluid  
2-Involvement of 
nursing staff  
3- Partnership with 
local sexual health 
service 
Phillips  
UK (2013) 
(30) 
Quantitative 
(policy 
report) 
Patients 
aged 16-79 
attending 
AMU  
21  Standard 
serology 
Existing 
AMU staff 
No data 84%  
154/183 
32.5% 
4122/ 
12682 
14 93% 1- Short length of stay 
on AMU 
 
1- High level of 
commitment from and 
ownership by the 
AMU staff, especially 
nurses. 
2- Partnership with 
HIV unit  Palfreeman  
UK (2013) 
(29) 
Quantitative 
(policy 
report) 
Patients 
aged 15-59 
attending 
AMU 
12 Standard 
serology 
Existing 
AMU staff 
No data No  
data 
22.5%  
1399/6225 
15 100% 1- Short length of stay 
on AMU 
 
1- Senior leadership 
support 
2- Partnership with 
HIV unit  
Rayment   
UK (2012) 
(26) 
Quantitative 
(pilot) 
Staff filled in 
Question-
naires 
(71 in ED, 41 
in AMU) 
Patient aged 
16-65; and 
staff in ED 
and AMU  
 
3 Non-rapid 
oral fluid in 
ED 
standard 
serology in 
AMU 
Research 
team 
62.3% 
3433/ 
5505  
ED 
42.2% 
548/12
98AMU 
61.8% 
2121/ 
3433  
ED 
70.1% 
384/ 548 
AMU 
38.3 % 
2121/ 
5505  
ED 
29.6% 
384/1298 
AMU 
4 in ED 
4 in AMU 
100% ED 
100% AMU 
1- Lack of privacy (58% 
in ED & 44% in AMU) 
2- Lack of time (53% in 
ED- 40% in AMU)  
3- Short stay on AMU 
4- Need for additional 
training (82% in ED; 
and 65% in AMU) 
1- Not using a point of 
care tests 
2- Partnership with 
local sexual health 
service 
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1st author, 
country 
(year)  
Citation 
Type of 
study 
Setting and 
population 
Duration 
of study 
(months) 
Type of 
HIV test & 
staff 
offering 
test 
HIV 
test 
offer 
HIV test 
uptake 
HIV 
testing 
coverage 
Number of 
new HIV 
diagnoses 
Proportion 
of new 
cases 
linked to 
care 
Barriers to HIV testing Facilitators of HIV 
testing 
Ellis 
UK (2011) 
(32) 
Quantitative 
(pilot) 
Patients 
aged >18 
years 
attending 
AMU 
3 Standard 
serology 
Existing 
AMU staff 
13.1% 
478/ 
3645 
82.8% 
396/ 
478 
10.9% 
396/ 
3645 
2 100% 1- Low risk perception 
was the main reason 
for refusal 
2- Lack of time 
1- Partnership with 
local infectious 
diseases unit (training 
and results/linkage to 
care handling) 
Bath  
UK (2015) 
(31) 
Quantitative 
(pilot) 
Patients 
aged >16 
years 
attending 
ED 
3 Standard 
serology 
Existing 
ED staff 
No 
data 
No 
data 
30% 
2828/ 
9297 
8 87.5%  1- Partnership with 
local HIV unit (training 
and results/linkage to 
care handling) 
2- Highly motivated 
and committed ED 
staff 
Thornton  
UK (2012) 
(27) 
Qualitative 
(focus 
groups 
before and 
after a 
testing pilot) 
Staff in ED 
and AMU 
 
 
3 n/a n/a n/a n/a n/a n/a 1- Exceptionalism of 
HIV as a medical 
condition 
2- lack of time  
3- Confidentiality and 
privacy concerns,  
4- Results’ governance 
and follow up concerns 
5- Perception of the 
need for specialist 
knowledge to offer an 
HIV test 
1- Lack of targeted 
testing 
Lin X 
US (2014) 
(35) 
Quantitative 
(policy 
report) 
Patients 
aged ≥ 13 
years old 
attending 
ED 
9 Standard 
serology 
Existing 
ED staff 
No data No 
data 
26%  
12568 
/48338 
77 74%  1- Electronic health 
record prompts HIV 
test offer for all 
eligible patients.       
2- Change from rapid 
testing to venous 
sampling                          
3- Staff education 
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1st author, 
country 
(year) 
Citation 
Type of 
study 
Setting and 
population 
Duration 
of study 
(months) 
Type of 
HIV test & 
staff 
offering 
test 
Offer of 
HIV 
testing 
Uptake 
of HIV 
testing 
offer 
HIV testing 
coverage 
Number of 
new HIV 
diagnoses 
Proportion 
of new 
cases 
linked to 
care 
Barriers to HIV testing Facilitators of HIV 
testing 
Knapp  
US (2014) 
(39) 
Mixed 
(policy 
report)  
(in-depth 
interviews 
for staff) 
Patients 
aged 13-64 
attending & 
Staff working 
in ED 
 
60 Rapid oral 
fluid test 
Existing ED 
staff 
No data  No 
data 
2055 tests 
over 5 
years 
No  
data 
No  
data 
1- Lack of senior 
leadership engagement 
2- Lack of frontline staff 
involvement in the 
planning process           
3- Inadequate training   
4- Lack of adequate 
system of monitoring and 
feedback to staff in the 
frontline 
1- The enthusiasm 
of two clinical 
champions 
 
 
Setse, US 
(2014) 
(36) 
Quantitative 
(supported 
policy)  
Patients 
aged ≥ 13 
attending ED 
56 Rapid oral 
fluid test 
Research 
team 
No data 75.4% 
24596/3
2633 
No  
data 
335 100% 1- Female sex                
2- Old age 
1- Research team 
support in offering 
and conducting HIV 
testing 
Brown C 
US (2007) 
(34) 
Quantitative 
(pilot) 
Patient aged 
13-64 
attending ED 
 
 3 
Rapid oral 
fluid test 
Research 
team 
31.4% 
4187/ 
13240  
59.4% 
2486/ 
4187 
18.7 % 
2486/ 
13240  
9 88.9% 1- Old age 1- Lack of written 
consent and pre-
test counselling 
requirement 
Brown US 
(2008) 
(37) 
 
 
Quantitative 
(Survey) 
Patients 
aged 13-64 
attending ED 
 
9 Rapid oral 
fluid test 
Research 
team 
No 
data 
53% 
5232/98
26 
No 
data 
No 
data 
No 
data 
1- Low risk perception 
was the main reason for 
refusal 
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1st author, 
country 
(year) 
Citation 
Type of 
study 
Setting and 
population 
Duration 
of study 
(months) 
Type of 
HIV test & 
staff 
offering 
test 
HIV test 
offer 
HIV 
test 
uptake 
HIV testing 
coverage 
Number of 
new HIV 
diagnoses 
Proportion 
of new 
cases 
linked to 
care 
Barriers to HIV testing Facilitators of HIV 
testing 
Hecht 
US (2011) 
(38) 
Quantitative 
(Survey for 
staff and 
patients) 
Patients 
aged 18-65 
attending & 
staff working 
in 2EDs 
 
18 n/a n/a n/a n/a n/a n/a Patients’ views:           
1-Privacy/confidentiality 
concerns                        
2-Perception of low risk 
Staff views:                  
1- Lack of time               
2-Privacy/confidentiality 
concerns                        
3- Fear of influx of 
patients to ED  
 
4- Linkage to care 
concerns 
 
 
Arbelaez  
US (2012) 
(33) 
Quantitative   
(Survey of 
staff before 
and after a 
testing 
pilot) 
Medical staff 
in ED 
 
6 Rapid oral 
fluid  
Existing ED 
staff 
 
n/a n/a n/a n/a n/a  
Pre-programme: 
1-Lack of resources; 70% 
2-Time constraints; 51% 
3-Follow-up worries; 50% 
 
Post-programme: 
1-Inadequate time; 62% 
2-lack of resources; 60% 
3-Follow-up worries; 59% 
 
 
¶ HIV test offer refers to proportion of patients offered an HIV out of those eligible for HIV testing. 
§ HIV offer uptake refers to proportion of patients accepted an HIV test offer out of those offered a test. 
Ι HIV test coverage refers to number of patients tested for HIV out of those eligible for testing. 
¶ ¶ Linkage of patients tested positive for HIV to care refers to percentage of patients tested positive who were informed of their positive results and seen by an HIV care provider out of 
those diagnosed with new HIV infection. 
§§ Factors facilitating HIV testing refer to factors helping in increasing the HIV testing offer and/or uptake. 
Θ Barriers to HIV testing refer to factors hindering the HIV testing offer and/or uptake. 
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Supplementary Materaial1: PRISMA Checklist 
Section/topic  # Checklist item  
TITLE  
Title  1 Identify the report as a systematic review, meta-analysis, or both.  
ABSTRACT  
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and implications 
of key findings; systematic review registration number.  
INTRODUCTION  
Rationale  3 Describe the rationale for the review in the context of what is already known.  
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
METHODS  
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact 
with study authors to identify additional studies) in the search and date last 
searched.  
Search  8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated.  
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, 
in duplicate) and any processes for obtaining and confirming data from 
investigators.  
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).  
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
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Section/topic  # Checklist item  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publication bias, selective reporting within studies).  
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified.  
RESULTS  
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.  
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study 
size, PICOS, follow-up period) and provide the citations.  
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]).  
DISCUSSION  
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, users, 
and policy makers).  
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-
level (e.g., incomplete retrieval of identified research, reporting bias).  
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
FUNDING  
Funding  27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review.  
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Supplementary Material 2: Search plan  
 
1- Search question: 
What are the facilitators and barriers for routine HIV testing in British and American hospitals? 
 
2-Search concepts: 
Facilitators and barriers 
Routine HIV testing 
American and British hospitals 
 
3- Databases: 
MEDLINE 
EMBASE 
   
4- choosing search terms (subject headings are also used): 
  
Facilitators and barriers: 
Facilitate, enable, barrier, obstacle, hurdle, hinder, uptake, coverage, sustain 
  
Routine HIV testing: 
Opt-out, screening, universal, testing, HIV, human immunodeficiency virus, 
  
America and UK : 
United Kingdom, UK, Britain, Great Britain, GB, GBR,  England, Wales, Scotland, North Ireland, 
British, English, Welsh, Scottish, Northern Irish, America, American, North America, Northern 
American, United States, US, United States of America and USA 
  
  
5- compiling search strategy and running the search: 
  
(facilitat* or enable or barrier or obstacle or hurdle or hinder or uptake or coverage or sustain*) 
  
And 
  
(routine HIV test* or routine human immunodeficiency virus test* or routine HIV screen* or routine 
human immunodeficiency virus screen* or opt-out HIV test* or opt-out human immunodeficiency 
test* or opt-out HIV screen* or opt-out human immunodeficiency screen* or universal HIV screen* 
or universal human immunodeficiency virus screen* or universal HIV test* or universal human 
immunodeficiency virus test*) 
  
And 
  
(United Kingdom or UK or Britain or England or Wales or Scotland or North Ireland or British or 
English or Welsh or Scottish or Northern Irish or America or American or North America or Northern 
American or United States or US or United States of America or NY or New York or London or USA) 
  
6-Search limit: 
The search was limited to 2006 to current and 2008 to current for American and British literature, 
respectively (Since the publication of HIV testing guidelines) 
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Supplementary Material 3: Data extraction tool 
Author (s): 
Year of publication: 
Country:  
Setting (ED (US) vs AMU or A &E (UK)): 
Study design: 
Population: 
Age group: 
Duration of reported period: 
Type of HIV test used (rapid vs non-rapid): 
Staff group offering the HIV test (existing staff vs HIV screening staff): 
Number of subjects eligible for screening: 
HIV test offer rate (number of patients offered / number of eligible patients): 
Uptake rate (number of patients tested / number of patients offered): 
HIV test coverage (number of patients tested/ number of eligible patients): 
Positivity rate (number of patients tested positive / number of patients tested): 
Number of new HIV diagnoses: 
Proportion of patients newly diagnosed who were linked to care: 
Factors facilitating testing  
Barriers to testing 
 
Comments    
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Supplementary Material 4: Risk of bias assessment in the quantitative studies included in the 
review 
 
Author  
 
(Country, 
year) 
Is the 
sampling 
strategy 
relevant to 
address the 
quantitative 
research 
question?  
Is the sample 
representative 
of the 
population 
understudy? 
 
Are 
measurements 
appropriate  
 
Is there an 
acceptable 
response 
rate  
 
 
 
Overall score 
 
Rayment M 
(UK, 2013)  
 
Yes Can’t tell Yes Yes 75% 
Phillips D  
(UK, 2013) 
 
Yes Can’t tell Yes Yes 75% 
Palfreeman A 
(UK, 2013) 
 
Yes Can’t tell Yes Yes 75% 
Rayment M 
(UK, 2012) 
 
Yes No Yes Yes 75% 
Ellis S  
(UK, 2011) 
 
Yes Can’t tell Yes Yes 75% 
Bath R  
(UK, 2015) 
 
Yes Can’t tell Yes Yes 75% 
Lin X  
(US, 2014) 
 
Yes Can’t tell Yes Yes 75% 
Setse RW (US, 
2014) 
 
Yes Can’t tell Yes Yes 75% 
Brown J  
(US, 2007) 
 
Yes Can’t tell Yes Yes 75% 
Brown J  
(US, 2008) 
 
Yes Can’t tell Yes Can’t tell 50% 
Hecht CR (US, 
2011) 
 
Yes Yes Yes Can’t tell 75% 
Arbelaez C 
(US, 2012) 
 
Yes Can’t tell Yes Yes 75% 
 
 
